A — Agilent Technologies, Inc.

Agilent's Q3 FY26 results beat consensus: revenue rose 8.1% to $1.878B versus the $1.84B consensus, and non-GAAP EPS of $1.62 beat by $0.13. Management raised FY26 revenue guidance to $7.49–$7.51B and non-GAAP EPS to $6.18–$6.21. Multiple banks raised targets to $175–$190, and the stock sits near its 52-week high, so market sentiment is clearly bullish.

The data show a clear cyclical recovery, not just a blip. FY24 was the trough, with quarterly revenue ranging from $1.573B to $1.701B. Through FY25 and into FY26, growth re-accelerated: the last three reported quarters were $1.798B, $1.835B, and $1.878B, with Q3 FY26 revenue up 8.1% YoY. GAAP operating margin in Q3 FY26 expanded to 23.6% from 20.7% in the prior-year quarter, and gross margin improved to 55.5% from 52.6%. Net income is lumpier because of tax and one-off items, but the operating trend is steadily positive. Free cash flow also snapped back in Q3 FY26 to $439M after weaker H1 FY26 prints.

As of 2026-08-27, the stock is fairly valued versus its own history, not obviously cheap or expensive. The trailing P/E is 30.98, essentially in line with the 5-year average of 31.64, and the P/S of 6.04 is close to the 5-year average of 5.96. On forward non-GAAP earnings, using the FY26 midpoint of $6.19, the stock trades at roughly 25.5x forward earnings. That is reasonable for a high-quality life sciences tools franchise, but the PEG of 1.64 suggests the growth is already being paid for.

At $157.69 as of 2026-08-27, the stock is priced for continued recovery and margin expansion rather than for a beat-and-raise surprise. The 25.5x forward multiple only works if Agilent delivers on its raised FY26 guidance and sustains mid-single-digit-plus growth into FY27. If FY27 EPS estimates migrate higher toward $6.75–$7.00, the current price could prove reasonable. But if the cyclical recovery stalls or margin gains fade, the multiple has little cushion. The market is currently rewarding momentum; the playbook favors holding or buying on weakness rather than chasing the overbought print.

As of 2026-08-27, RSI stood at 70.26, which is overbought. Price was 5.88% above the 20-day SMA, 12.98% above the 50-day SMA, and 19.94% above the 200-day SMA, so the trend is clearly up and the stock is extended short-term. The stock is also just below the 52-week high of $163.75. Implication: the trend is bullish, but this is not an ideal fresh-entry point; a pullback toward the 20-day or 50-day SMA would improve the risk/reward.

• Life sciences tools and analytical instruments are emerging from a customer destocking cycle, with synchronized demand recovery across pharma and applied markets.
• China sentiment has stabilized and is now a modest tailwind rather than a headwind, though geopolitical and tariff risks remain.
• Biopharma reshoring and advanced therapeutics, especially cell and gene therapy tooling, are driving above-market growth.
• Regulation-driven testing demand, including PFAS environmental testing, supports applied markets.
• Interest rates and equity multiples remain a swing factor for a 31x trailing P/E stock; any reset in rates could compress the multiple.

• Q4 and full-year FY26 earnings release in late November/early December 2026, which should include initial FY27 guidance and order commentary.
• Continued execution of the Ignite Operating System to sustain non-GAAP operating margin expansion.
• Diagnostic assay approvals, including the recent PD-L1 approvals in new cancer indications, adding pharmaDx growth.
• Further order improvement in China and LC-MS/advanced therapeutics end markets.

• Valuation is full and the stock is overbought; any disappointment in FY27 guidance could trigger multiple compression.
• Q3 FY26 benefited from a $0.06 per share tariff refund and roughly 110 bps of margin tailwind that is unlikely to repeat.
• China exposure remains a geopolitical and policy risk despite stabilizing sentiment.
• Competitive pressure in LC-MS and analytical instruments could limit above-market growth.
• Free cash flow has lagged net income at times; TTM FCF is solid but not as robust as earnings growth suggests.

Agilent is a high-quality life sciences tools franchise in the middle of a genuine demand recovery, with margin expansion, a clean balance sheet, and raised guidance. The stock is not cheap, but the forward P/E is reasonable relative to its own history and the earnings trajectory. I lean bullish, with the caveat that the best risk/reward is likely on a pullback rather than at the current overbought level.

I applied a forward P/E of 28x to the midpoint of FY26 non-GAAP EPS guidance of $6.19, a slight discount to Agilent's 5-year average trailing P/E of 31.64 to account for the fact that the recovery is already underway and growth may normalize. This yields a fair value of approximately $173.46, near the consensus target but independently derived from the observed multiple and earnings guidance.